## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: **09/436,347** Group Art Unit: 1643

Confirmation No.: 6491 Examiner: A.M. Harris

Filed: 9 November 1999

Inventor: Christine A. WHITE *et al*.

For: Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies

(as amended)

Mail Stop **AF** Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## REPLY UNDER 37 C.F.R. § 1.111(a) OR § 1.116(b)

Sir:

This communication responds to the Office letter mailed 17 July 2007, setting a three month period for response. As this reply is filed within the stated period, it is timely.

Applicant believes that no fee is required but requests that the Director debit any fee necessary for entry or consideration of this paper from our Deposit Account number 18-1260.

Applicant thanks the examiner for considering the reply filed 27 April 2007 and for withdrawing all of the objections and rejections stated previously.

Insofar as this reply is required to comply with § 1.116(b), the arguments set forth below are necessary and were not earlier presented because they respond to rejections stated for the first time in the Office action mailed 17 July 2007. Applicant requests that the examiner enter these remarks and reconsider the outstanding grounds of rejection.

BI 0525CP1 7 AUGUST 2007 – PAGE 1